172 related articles for article (PubMed ID: 37786375)
21. [Anti-tumor effect and impact on tumor immune microenvironment of tumor-targeted Salmonella VNP20009].
Han YH; Lai XH; Le ZW; Hua ZC
Yao Xue Xue Bao; 2016 Sep; 51(9):1417-22. PubMed ID: 29924525
[TBL] [Abstract][Full Text] [Related]
22. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.
Prabhakar S; Taherian M; Gianni D; Conlon TJ; Fulci G; Brockmann J; Stemmer-Rachamimov A; Sena-Esteves M; Breakefield XO; Brenner GJ
Hum Gene Ther; 2013 Feb; 24(2):152-62. PubMed ID: 23140466
[TBL] [Abstract][Full Text] [Related]
23. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models.
Jia LJ; Wei DP; Sun QM; Huang Y; Wu Q; Hua ZC
Cancer Sci; 2007 Jul; 98(7):1107-12. PubMed ID: 17498202
[TBL] [Abstract][Full Text] [Related]
24. Management of neurofibromatosis type 2 and schwannomatosis associated peripheral and intraspinal schwannomas: influence of surgery, genetics, and localization.
Gugel I; Grimm F; Tatagiba M; Schuhmann MU; Zipfel J
J Neurooncol; 2022 Sep; 159(2):271-279. PubMed ID: 35771312
[TBL] [Abstract][Full Text] [Related]
25. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.
Caltabiano R; Magro G; Polizzi A; Praticò AD; Ortensi A; D'Orazi V; Panunzi A; Milone P; Maiolino L; Nicita F; Capone GL; Sestini R; Paganini I; Muglia M; Cavallaro S; Lanzafame S; Papi L; Ruggieri M
Childs Nerv Syst; 2017 Jun; 33(6):933-940. PubMed ID: 28365909
[TBL] [Abstract][Full Text] [Related]
26. Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.
Chen J; Yang B; Cheng X; Qiao Y; Tang B; Chen G; Wei J; Liu X; Cheng W; Du P; Huang X; Jiang W; Hu Q; Hu Y; Li J; Hua ZC
Cancer Sci; 2012 Feb; 103(2):325-33. PubMed ID: 22054098
[TBL] [Abstract][Full Text] [Related]
27. Complete genome sequence of Salmonella enterica serovar Typhimurium VNP20009, a strain engineered for tumor targeting.
Broadway KM; Modise T; Jensen RV; Scharf BE
J Biotechnol; 2014 Dec; 192 Pt A():177-8. PubMed ID: 25046822
[TBL] [Abstract][Full Text] [Related]
28. The importance of nerve microenvironment for schwannoma development.
Schulz A; Büttner R; Hagel C; Baader SL; Kluwe L; Salamon J; Mautner VF; Mindos T; Parkinson DB; Gehlhausen JR; Clapp DW; Morrison H
Acta Neuropathol; 2016 Aug; 132(2):289-307. PubMed ID: 27236462
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Toso JF; Gill VJ; Hwu P; Marincola FM; Restifo NP; Schwartzentruber DJ; Sherry RM; Topalian SL; Yang JC; Stock F; Freezer LJ; Morton KE; Seipp C; Haworth L; Mavroukakis S; White D; MacDonald S; Mao J; Sznol M; Rosenberg SA
J Clin Oncol; 2002 Jan; 20(1):142-52. PubMed ID: 11773163
[TBL] [Abstract][Full Text] [Related]
30. Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy.
Sun Y; Guo Y; Liu X; Liu J; Sun H; Li Z; Wen M; Jiang SN; Tan W; Zheng JH
Theranostics; 2023; 13(15):5546-5560. PubMed ID: 37908720
[No Abstract] [Full Text] [Related]
31. Optimizing the restored chemotactic behavior of anticancer agent Salmonella enterica serovar Typhimurium VNP20009.
Broadway KM; Suh S; Behkam B; Scharf BE
J Biotechnol; 2017 Jun; 251():76-83. PubMed ID: 28433721
[TBL] [Abstract][Full Text] [Related]
32. Rescuing chemotaxis of the anticancer agent Salmonella enterica serovar Typhimurium VNP20009.
Broadway KM; Denson EA; Jensen RV; Scharf BE
J Biotechnol; 2015 Oct; 211():117-20. PubMed ID: 26200833
[TBL] [Abstract][Full Text] [Related]
33. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
[TBL] [Abstract][Full Text] [Related]
34. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.
Messerli SM; Prabhakar S; Tang Y; Mahmood U; Giovannini M; Weissleder R; Bronson R; Martuza R; Rabkin S; Breakefield XO
Hum Gene Ther; 2006 Jan; 17(1):20-30. PubMed ID: 16409122
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
Paldor I; Abbadi S; Bonne N; Ye X; Rodriguez FJ; Rowshanshad D; Itzoe M; Vigilar V; Giovannini M; Brem H; Blakeley JO; Tyler BM
J Neurooncol; 2017 Oct; 135(1):47-56. PubMed ID: 28735458
[TBL] [Abstract][Full Text] [Related]
36. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
37. Combined Cellular Thermometry Reveals That
Wu L; Chen F; Chang X; Li L; Yin X; Li C; Wang F; Li C; Xu Q; Zhuang H; Gu N; Hua ZC
J Am Chem Soc; 2022 Oct; 144(42):19396-19409. PubMed ID: 36228296
[TBL] [Abstract][Full Text] [Related]
38. Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy.
Liang K; Liu Q; Li P; Luo H; Wang H; Kong Q
Cancer Lett; 2019 Apr; 448():168-181. PubMed ID: 30753837
[TBL] [Abstract][Full Text] [Related]
39. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model.
Chen G; Tang B; Yang BY; Chen JX; Zhou JH; Li JH; Hua ZC
Appl Microbiol Biotechnol; 2013 May; 97(10):4393-401. PubMed ID: 22868826
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effects of arsenic trioxide combined with
Zhao Q; Wang Y; Li WT
J Gastrointest Oncol; 2021 Aug; 12(4):1732-1742. PubMed ID: 34532123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
